APRICUS BIOSCIENCES INC

Inactive Instrument

Analyst Reco. Apricus Biosciences Inc Nasdaq

Equities

US03832V3078

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	23-09-21	MT
Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	23-09-21	MT
Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	23-09-21	MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	23-05-16	MT
Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	23-03-24	MT
B. Riley Lowers Seelos Therapeutics' PT to $4 from $6, Conservatively Adjusts for Higher Cost of Capital to Support Higher Operating Expenses Ramp; Keeps Buy Rating	22-03-14	MT
Cantor Fitzgerald Adjusts Seelos Therapeutics' Price Target to $3 from $5, Maintains Overweight Rating	22-03-08	MT
Cantor Fitzgerald Adjusts Seelos Therapeutics' Price Target to $3 From $5, Reiterates Overweight Rating	22-03-08	MT
B. Riley Lowers Seelos Therapeutics' Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
SEELOS THERAPEUTICS : Roth Capital Upgrades Seelos Therapeutics to Buy from Neutral, Adjusts Price Target to $8 from $2.50	21-09-27	MT
SEELOS THERAPEUTICS : B. Riley Lowers Seelos Therapeutics' PT to $11 from $15, Keeps Buy Rating	21-08-18	MT
SEELOS THERAPEUTICS : Roth Capital Adjusts Price Target on Seelos Therapeutics to $2.50 From $4, Maintains Neutral Rating	21-08-10	MT
SEELOS THERAPEUTICS : Guggenheim Starts Seelos Therapeutics at Buy With $8 Price Target	21-07-01	MT
SEELOS THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Seelos Therapeutics With Overweight Rating, $10 Price Target	21-06-01	MT
SEELOS THERAPEUTICS : B. Riley Starts Seelos Therapeutics at Buy with $15 PT, Says High-Value Neuroscience Pipeline Coming Together	21-03-30	MT
SEELOS THERAPEUTICS : BTIG Starts Seelos Therapeutics at Buy with Street-High $14 Price Target	21-03-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer